Cabaletta Bio
CABA· Manufacturing· Fiscal year ends in December
CEO pay in FY2024Stock -90.0% in FY2024
Steven Nichtberger, M.D. is the CEO of Cabaletta Bio and was paid $8.1M in FY2024 (Dec), up 68%.
Pay$100 in the stock at the end of FY21 → $60
Executives3
See all- 1Steven Nichtberger, M.D.President and Chief Executive OfficerFY2024
- 2David J. Chang, M.D., M.P.H.Chief Medical OfficerFY2024
- 3Gwendolyn BinderPresident, Science and TechnologyFY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCabaletta Bio paid its 3 named executives $14.8M in total in FY2024 (Dec). CEO Steven Nichtberger, M.D. was paid $8.1M of that.
| Name | |||
|---|---|---|---|
| Steven Nichtberger, M.D.President and Chief Executive Officer | |||
| David J. Chang, M.D., M.P.H.Chief Medical Officer | |||
| Gwendolyn BinderPresident, Science and Technology |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Cabaletta Bio. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Mark Simon, MBADirector · 7 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance—Paid as an executive
- Richard Henriques, MBADirector · 6 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 23, 2026 | FY2025 |
| Proxy statement | DEF 14A | May 13, 2025 | FY2024 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 23, 2024 | FY2023 |
| Annual report | 10-K | Mar 21, 2024 | FY2023 |
